User menu

Zoledronic acid (ZOL) treatment (Rx) of >= 2 years in patients (pts) with metastatic bone disease (MBD) or multiple myeloma (MM): Six-month results from the LOTUZ study

Bibliographic reference Duck, L. ; Delforge, Michel ; Doyan, C. ; Wildiers, H. ; MacDonald, K. ; et. al. Zoledronic acid (ZOL) treatment (Rx) of >= 2 years in patients (pts) with metastatic bone disease (MBD) or multiple myeloma (MM): Six-month results from the LOTUZ study.45th Annual Meeting of the American-Society-of-Clinical-Oncology (Orlando(Fl), May 29-jun 02, 2009). In: Journal of Clinical Oncology, Vol. 27, no. 15 (2009)
Permanent URL http://hdl.handle.net/2078.1/58530